In the future, functional testing could help assess the efficacy of PI3Kδ inhibitors in APDS and other diseases with abnormal PI3K/Akt signaling, e.g. PTEN deficiency, which could help provide existing therapy options for more patients and to monitor therapy. This evidence concerns the gene AKT1 and activated PI3K-delta syndrome.